What Arcadia Biosciences, Inc. reported on August 13, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|
| Total Revenue | $1.6M | $1.3M | +24.35% |
| Profit | $1.8M | $856K | +105.02% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingArcadia Biosciences, Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$0.70
Aug 12, 2026
Close after
$0.62
Aug 14, 2026
Move
-10.77%
691.69K shares traded, against a normal 128.02K
What Arcadia Biosciences, Inc. does
Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products.
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from Arcadia Biosciences’s earnings press release (an Item 2.02 8-K) filed August 13, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.
